FMP

FMP

Enter

ALEC - Alector, Inc.

Financial Summary of Alector, Inc.(ALEC), Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of n

photo-url-https://financialmodelingprep.com/image-stock/ALEC.png

Alector, Inc.

ALEC

NASDAQ

Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, a humanized recombinant monoclonal antibody, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease; and AL003, which is in Phase I clinical trial for the treatment of Alzheimer's disease. In addition, its products in development stage include AL044 that targets MS4A4A, a risk gene for Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.

4.58 USD

0.005 (0.109%)

About

ceo

Dr. Arnon Rosenthal Ph.D.

sector

Healthcare

industry

Biotechnology

website

https://www.alector.com

exchange

NASDAQ

Description

Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, a humanized recombinant monoclonal antibody, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease; and AL003, which is in Phase I clinical trial for the treatment of Alzheimer's...

CIK

0001653087

ISIN

US0144421072

CUSIP

014442107

Address

131 Oyster Point Boulevard

Phone

415 231 5660

Country

US

Employee

244

IPO Date

Feb 7, 2019

Summary

CIK

0001653087

Exchange

NASDAQ

Industry

Biotechnology

Sector

Healthcare

CUSIP

014442107

ISIN

US0144421072

Country

US

Price

4.58

Beta

0.77

Volume Avg.

624.76k

Market Cap

440.96M

Shares

-

52-Week

3.66-9.065

DCF

-0.02

ROE

-

ROA

-

Operating Margin

-

Debt/Equity

-

P/E

-3.29

P/B

-

Website

https://www.alector.com

Historical Prices

We are unable to load the chart at this time.

fmp-logo

Financial Statement

We are unable to load the chart at this time.

fmp-logo

Earnings

We are unable to load the chart at this time.

fmp-logo

Upgrades and Downgrades

We are unable to load this data!

fmp-logo

People Also Watch

page loading card

Latest ALEC News

It looks like there's no news available.

fmp-logo
FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedinfacebookinstagram
2017-2024 © Financial Modeling Prep